Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases: International Multicenter Study on Efficacy and Toxicity

• Published in: Cardiovascular and interventional radiology Vol. 42; no. 3; pp. 413 - 425
• Main Authors: Braat, A. J. A. T., Kappadath, S. C., Ahmadzadehfar, H., Stothers, C. L., Frilling, A., Deroose, C. M., Flamen, P., Brown, D. B., Sze, D. Y., Mahvash, A., Lam, M. G. E. H.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.03.2019; Springer Nature B.V
• Subjects: Cardiology; Clinical Investigation; Complications; Disease control; Imaging; Interventional Oncology; Liver; Load distribution; Lymphopenia; Medical prognosis; Medicine; Medicine & Public Health; Metastases; Metastasis; Microspheres; Neoplasms; Neuroendocrine tumors; Nuclear Medicine; Parameters; Patients; Radiology; Survival; Toxicity; Tumors; Ultrasound; Radioembolization; NET; Neuroendocrine tumor; NEN; SIRT
• ISSN: 0174-1551; 1432-086X
• DOI: 10.1007/s00270-018-2148-0

Purpose Radioembolization of liver metastases of neuroendocrine neoplasms (NEN) has shown promising results; however, the current literature is of limited quality. A large international, multicentre retrospective study was designed to address several shortcomings of the current literature. Materials 244 NEN patients with different NEN grades were included. Methods Primary outcome parameters were radiologic response 3 and 6 months after treatment according to RECIST 1.1 and mRECIST. Secondary outcome parameters included clinical response, clinical and biochemical toxicities. Results Radioembolization resulted in CR in 2%, PR in 14%, SD in 75% and PD 9% according to RECIST 1.1 and in CR in 8%, PR in 35%, SD in 48% and PD in 9% according to mRECIST. Objective response rates improved over time in 20% and 26% according to RECIST 1.1. and mRECIST, respectively. Most common new grade 3–4 biochemical toxicity was lymphocytopenia (6.7%). No unexpected clinical toxicities occurred. Radioembolization-specific complications occurred in < 4%. In symptomatic patients, improvement and resolution of symptoms occurred in 44% and 34%, respectively. Median overall survival from first radioembolization was 3.7, 2.7 and 0.7 years for G1, G2 and G3, respectively. Objective response is independent of NEN grade or primary tumour origin. Significant prognostic factors for survival were NEN grade/Ki67 index, ≥ 75% intrahepatic tumour load, the presence of extrahepatic disease and disease control rate according to RECIST 1.1. Conclusion Safety and efficacy of radioembolization in NEN patients was confirmed with a high disease control rate of 91% in progressive patients and alleviation of NEN-related symptoms in 79% of symptomatic patients. Level of evidence 4.